Covid-19 vaccine ‘CanSino’ appears safe in first human trial


A Covid-19 vaccine has been tested for the first time in humans and it appears to be safe and induces a rapid immune response.

Researchers at China’s CanSino Biologics Inc said in The Lancet Journal that blood samples from a group of 108 vaccinated adults showed both neutralizing antibodies and T-cell responses against the novel coronavirus in most of those tested.

“These results represent an important milestone. The trial demonstrates that a single dose of the new adenovirus type 5 vectored Covid-19 (Ad5-nCoV) vaccine produces virus-specific antibodies and T cells in 14 days, making it a potential candidate for further investigation,” Professor Wei Chen of Beijing Institute of Biotechnology, also the co-author of the research, said in a statement.

This is just a first step, however, further studies are need to confirm if the vaccine indeed protects one against the new coronavirus.

“The ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from Covid-19… we are still long way from this vaccine being available to all,” Chen added.


Please enter your comment!
Please enter your name here